DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,036 | +10.4% | 19,391 | +48.8% | 0.01% | -20.0% |
| Q4 2022 | $362,336 | -19.1% | 13,029 | -10.8% | 0.01% | -23.1% |
| Q3 2022 | $448,000 | -0.4% | 14,607 | -4.4% | 0.01% | -7.1% |
| Q2 2022 | $450,000 | +67.9% | 15,285 | +187.5% | 0.01% | +27.3% |
| Q3 2021 | $268,000 | -64.2% | 5,317 | -44.3% | 0.01% | -65.6% |
| Q2 2021 | $748,000 | -48.1% | 9,539 | -62.2% | 0.03% | -50.0% |
| Q1 2021 | $1,441,000 | +126.6% | 25,241 | +232.3% | 0.06% | +204.8% |
| Q4 2020 | $636,000 | – | 7,595 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |